Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the…
21,400€
Echtzeit-Aktienkurs Celldex Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Celldex Therapeutics Inc. Aktie
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that…
Celldex Therapeutics (CLDX): Canaccord sieht knapp 200 % Kurspotenzial für die Aktie!
Celldex Therapeutics (CLDX) hat sich als innovatives biopharmazeutisches Unternehmen im Bereich der Mastzellbiologie etabliert. Mastzellen sind spezialisierte Zellen des Immunsystems.…
Celldex Therapeutics: Strong Pipeline But Uncertainties Remain
…
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate…
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 5.33% and 24.19%, respectively, for the quarter ended December 2024. Do the…
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
HAMPTON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the…
Celldex Therapeutics Aktie: Es kriselt!
Der Aktienkurs des Biopharma-Unternehmens Celldex Therapeutics verharrt aktuell bei 21,80 EUR, während Anleger gespannt auf die bevorstehende Veröffentlichung der Q4-Ergebnisse…
Celldex Therapeutics Strong Cash Runway Supports Barzolvolimabs Path To Market
…
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the…
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient…
Celldex Therapeutics: Rising High, With Room For Further Growth
…
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate…
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci,…
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced…